Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,564JPY
20 Feb 2017
Change (% chg)

¥-6 (-0.25%)
Prev Close
¥2,570
Open
¥2,547
Day's High
¥2,574
Day's Low
¥2,542
Volume
1,257,600
Avg. Vol
2,550,753
52-wk High
¥2,750
52-wk Low
¥2,192

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
Friday, 17 Feb 2017 06:00am EST 

ArQule Inc - : Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma . Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival .Primary endpoint of study is overall survival.  Full Article

Charleston Laboratories and Daiichi Sankyo receive complete response letter from FDA for CL-108
Friday, 3 Feb 2017 11:00am EST 

Charleston Laboratories : Charleston laboratories, inc. And daiichi sankyo, inc. Receive complete response letter from fda for new drug application for cl-108 (hydrocodone, acetaminophen, promethazine) tablets for oral use .Charleston laboratories - crl stated nda in its present form was not approved and provided guidance on information needed to resolve matters identified.  Full Article

Kite Pharma establishes strategic partnership with Daiichi Sankyo
Monday, 9 Jan 2017 04:23pm EST 

Kite Pharma Inc : Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan . Kite Pharma - Daiichi Sankyo will make an upfront payment to kite of $50 million . Kite Pharma says will be eligible to receive future payments totaling up to $200 million for development and commercial milestones . Kite Pharma says is also entitled to receive sales royalties in the low to mid double digit range .Kite pharma - under terms, Daiichi Sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in Japan.  Full Article

R&I affirms Daiichi Sankyo Co Ltd's rating at "AA" and announces negative outlook -R&I
Tuesday, 27 Dec 2016 01:35am EST 

Daiichi Sankyo Co Ltd <4568.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" -R&I .Rating outlook negative -R&I.  Full Article

U.S. FDA grants designation for HER2-targeting antibody drug conjugate DS-8201
Thursday, 1 Dec 2016 08:00am EST 

Daiichi Sankyo Co Ltd <4568.T>: u.s. Fda grants fast track designation for her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer .Daiichi sankyo -fda grantd fast track designation to investigational her2-targeting antibody drug conjugate ds-8201 for her2-positive metastatic breast cancer.  Full Article

Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond
Tuesday, 25 Oct 2016 09:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology . Under terms of agreement inspirion will receive an upfront payment .Inspiron will also receive milestone payments and royalties under terms of agreement.  Full Article

Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration
Wednesday, 12 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer .Daiichi Sankyo Co Ltd - financial terms of agreement were not disclosed.  Full Article

Daiichi Sankyo Co enters into a collaboration with Agonox Inc
Tuesday, 4 Oct 2016 08:00am EDT 

Daiichi Sankyo Co Ltd <4568.T>: Financial terms of agreement were not disclosed. . Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target .Entered into a strategic collaboration with Agonox, Inc.  Full Article

Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen
Friday, 15 Jul 2016 12:57am EDT 

Daiichi Sankyo Co Ltd <4568.T> : Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036 . Says it plans to issue 6th series unsecured corporate bonds worth 25 billion yen, with coupon rate of 1.200 percent and maturity date on July 25, 2046 .Subscription date on July 15 and payment date on July 25.  Full Article

Amgen and Daiichi Sankyo agree to commercialize Biosimilars in Japan
Wednesday, 13 Jul 2016 09:00pm EDT 

Amgen Inc : Amgen and daiichi sankyo announce agreement to commercialize biosimilars in japan . Under terms of agreement, amgen will remain responsible for development and manufacturing of biosimilars . Daiichi sankyo will file for marketing approval and be responsible for distribution and commercialization in japan . Amgen will have a limited right to co-promote products . Will retain all additional distribution and commercialization rights for biosimilar programs outside of japan . Specific financial terms of agreement were not disclosed .Deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab..  Full Article

More From Around the Web

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma